Loading...

APLLTD Alembic Pharmaceuticals Ltd Product Launches Announcement

lmbc

PLLT

Alembic Pharmaceuticals Ltd

(APLLTD)

2026 Announcement

USFDA final approval

Earnings Call Transcript

Audited results publication

Regulatory Compliance

Post-results conference rec...

Q4 & FY26 results

Investor Presentation

Audited Financial Results

Dividend Recommendation

Senior Management Resignation

Regulatory Compliance

Regulatory Compliance

Regulatory Compliance

Unclaimed Dividend Transfer

Director demise

Wholly Owned Subsidiary

Incorporation of Subsidiary

Regulatory notice

Newspaper publication for s...

Regulation 74(5) Certificate

Regulatory approval

Regulatory disclosure

Appointment and Relinquishment

Director Appointment

Trading window closure

One-on-one Meeting

Geographic Expansion

One-on-One Meeting

New Product Launch

Postal Ballot Notice

Regulatory approval

USFDA ANDA approval

Inspection outcome

Earnings Conference Call

Special Window for Transfer...

Unaudited financial results

New Product Launch

Conference Call

Director Appointment

Investors Presentation

Director appointment

Investor Presentation

Unaudited Financial Results

Director Appointment

Loss of share certificate

Regulatory approval

Conference Call

Board Meeting Intimation

USFDA tentative approval

Regulatory Compliance

Trading Window Closure

Share certificate loss

New Product Launch

Civil Litigation

Share transfer re-lodgement...

Notice of loss of share cer...

Share certificate loss notice

One on One Investor Meet

One-on-one meetings

Resignation of Senior Manag...

FDA Final Approval

Earnings Call Transcript

Share Claim Notice

FDA Approval Received

Financial Results

Conference Call Audio

Q2 FY26 Results

Investor Presentation

Financial Results Q2 FY26

Financial Results Q2

Board Meeting Results

Board Meeting Notice

Share Transfer Window

Share Claim Notice

Compliance Certificate

Email Change Notice

Investor Campaign Launch

Lost Share Certificate

Investor Meeting

Investor Meeting

Investor Meeting

Earnings Call Transcript

Financial Results

Auditor Appointments

Auditor Appointments

Conference Call Audio

Updated Contacts

Investor Presentation

Q1 FY26 Results

Management Change

Credit Rating Reaffirmed

FDA Approval Received

Conference Call Scheduled

Management Change

Management Change

Compliance Certificate

Management Change

Management Change

Shareholder Communication

Tax Demand Notice

Subsidiary Acquisition

Lost Share Certificate

Volume Movement Update

Management Change

Inspection Report Received

Investor Meeting

Corporate Guarantee Issued

Newspaper Publication

Annual General Meeting

Credit Rating Reaffirmed

Credit Rating Reaffirmed

USFDA Inspection

FDA Approval Received

Investor Meeting Update

FDA Approval Granted

Annual General Meeting

Investor Meeting

Investor Meeting

Claiming Shares Notice

Loss of Share Certificate

Management Change

Annual Compliance Report

Earnings Call Summary

Equity Shares Transfer

Financial Results

Audio Recording Submission

Management Changes

New Statutory Auditor

Investor Presentation

Financial Results Q4 2025

Shareholder Notice

USFDA Approvals

FDA Inspection Report

New Facility Commissioned

Conference Call Announcement

RTA Contact Update

Share Certificate Loss

Compliance Certificate

Loss of Share Certificate

USFDA Inspection Success

Subsidiary Formation

USFDA Inspection Update

Share Certificate Loss

Inspection Report Received

Director Appointment

Management Change

Tax Demand Notice

Investor Meeting

Financial Results

Director Retirement

Director Appointment

Investor Presentation

Q3 Financial Results

Shares Claim Notice

Management Change

Compliance Certificate

Management Change

Corporate Guarantee Issued

Successful Audit Pass

Subsidiary Dissolutions

FDA Inspection Results

Earnings Call Transcript

FDA Approval Granted

Financial Results Release

Post Results Call

Management Change

Quarterly Financial Results

Strong Q2 Results

Investor Meetings

Management Change

FDA Approval Received

Conference Call Notice

FDA Inspection Success

Compliance Certificate

FDA Approval Received

Management Change

FDA Inspection Report

USFDA Approval Granted

KYC Update Reminder

Share Certificate Loss

Lost Share Certificates

Management Change

Tax Assessment Notice

Tax Assessment Order

Investor Meeting

Management Resignation

Customs Order Received

Q1 FY25 Results

FDA Approval Granted

Analyst Meeting

Financial Results Publication

Audio Recording Submission

Contact Details Update

Financial Results

Investor Presentation

Conference Call

USFDA Inspection Completion

Conference Call

USFDA Approval News

Alembic Pharmaceuticals App...

Certificate Submission

Pharmaceutical Approval Ann...

USFDA Approvals

Meeting Notice Published

Regulatory Compliance

Pharmaceutical Approval

Annual General Meeting

Management Change

Management Change

Alembic Pharmaceuticals App...

Compliance Report

Memorandum Amendments

Financial Results Publication

Submission of Audio Recording

Investor Presentation

Financial Results Announcement

Approvals Received

Equity Share Certificates Lost

FDA Inspection Report

Notice Publication for Equi...

Shareholder Notice

Tax Assessment Order

Corporate Guarantees Issued

Shares Claim Advertisement

Conference Call

Certificate Issued

Newspaper Publication

Certificate Submission

Pharma Notice Publication

Assessment Orders Received

Compliance Confirmation

Acquisition of TicTwo Thera...

Penalty Imposed by GST Office

Directorate Change

Appointment of Independent ...

Newspaper Advertisement

Equity Share Certificate Lo...

Management Change

US FDA Inspection

Credit Rating Reaffirmation

Resumption of Manufacturing...

Investor Meeting

Published Financial Results

Audio Recording Submission

Investor Presentation

Financial Results

Resumption of Business Oper...

Investment in RIGImmune, Inc.

Conference Call

Certificate Submission

Restoration of Manufacturin...

Penalty Imposed

Corporate Guarantee Issued

US FDA Approvals

Management Change

Appointment of Senior Manag...

Management Appointment

Transcript of Conference Call

Audio Recording Submission

Investor Presentation

Financial Results Release

Conference Call

Compliance Certificate

Disruption of Operations

USFDA Product Approvals

Senior Management Change

Increase in Volume

Management Resignation

Debt Restructuring

Analyst / Investor Meeting

Restructuring Scheme

Financial Statements

Analyst/Investor Meeting

Financial Statements

Merger of Equals

Financial Statements

Conference Call

Merger of Equals

Certificate Submission

Financial Statements

Notice of Annual General Me...

Response to Market Activity

Analyst/Investor Meet

KYC and PAN details update

Claiming Shares

Management Changes

Management changes

Contract Renewal

Equity Offerings

Rights Offerings

Post Results Conference Call

Audio Recording Uploaded

Management Contact Update

Financial Results

Financial Statements

External Links:

Data:

USFDA grants final approval for Alembic’s Dapagliflozin 5 mg and 10 mg tablets, with 180 days of exclusive marketing eligibility and a sizable future addressable market.

AI Assistant

Alembic Pharmaceuticals Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.